Researchers explore TAF1's role in leukemia, revealing potential targeted therapies that could transform treatment approaches for acute myeloid leukemia.
Stephen Nimer, MD
Stephen D. Nimer, MD, is the director of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Articles by Stephen Nimer, MD
Stephen Nimer, MD, leukemia and lymphoma treatment specialist, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses results of a study which examined Musashi2 as a requirement for maintaining activated myelodysplastic syndrome (MDS) cells.
Latest Updated Articles
TAF1: A New Therapeutic Target for LeukemiaPublished: September 1st 2025 | Updated:
Dr. Stephen Nimer on MSI2 as a Requirement for Maintaining Activated MDS Stem CellsPublished: December 6th 2015 | Updated: